Executive Summary Overview Vascular Adhesion Protein-1 Structure Functions Mechanism of Action Role in various diseases Pipeline Therapeutics Comparative Analysis Mid Stage Products (Phase II) Comparative Analysis ASP8232: Astellas Pharma Drug Description Research and Development (The list continues) Pre-clinical Stage Products Comparative Analysis Therapeutic Assessment Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type Dormant Products Comparative Analysis Discontinued Products Comparative Analysis Appendix

Table 1: Total Drugs for VAP-1 Inhibitors Table 2: Mid Stage Products (Phase II) Table 3: Pre-clinical Stage Products Table 4: Assessment by Route of Administration for VAP-1 Inhibitors Table 5: Assessment by Stage and Route of Administration for VAP-1 Inhibitor Table 6: Assessment by Molecule Type for VAP-1 Inhibitors Table 7: Assessment by Stage and Molecule Type Table 8: Dormant Products Table 9: Discontinued Products Figure 1: Crystal structure of human VAP-1 in complex with pyridazinone inhibitors Figure 2: Function of VAP-1 in leukocyte adhesion and transmigration Figure 3: Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis Figure 4: Potential causative mechanisms of primary sclerosing cholangitis (PSC) Figure 5: Role of inflammatory chemokines in NASH Figure 6: Pipeline VAP-1 Inhibitors Figure 7: Total Drugs for VAP-1 Inhibitors Figure 8: Mid Stage Products (Phase II) Figure 9: Pre-clinical Stage Products Figure 10: Assessment by Route of Administration Figure 11: Assessment by Stage and Route of Administration Figure 12: Assessment by Molecule Type Figure 13: Assessment by Stage and Molecule Type Figure 14: Dormant Products Figure 15: Discontinued Products

Acorda Life Sciences Astellas Pharma Boehringer Ingelheim Faron Pharmaceuticals Proximagen Sucampo Pharmaceuticals